Transition to exhaustion: clues for cancer immunotherapy

Research on immune cells “exhausted” by chronic viral infection provides clues on how to refine cancer immunotherapy. The results were published Tuesday, Dec. 3 in Immunity. Scientists at Emory Vaccine Center, led by Rafi Ahmed, PhD, have learned about exhausted CD8 T cells, based on studying mice with chronic viral infections. In the presence of persistent virus or cancer, CD8 T cells lose much of their ability to fight disease, and display inhibitory checkpoint proteins Read more

Radiologists wrestle with robots - ethically

Emory bioethicist John Banja says: don’t believe the hype about AI replacing Read more

Opioids: crunching the Tweets

The aim is to be able to spot patterns of overdoses faster than prescription drug monitoring Read more

Nature

Beyond the usual suspects among Alzheimer’s proteins

If you’ve been paying attention to Alzheimer’s disease research, you’ve probably read a lot about beta-amyloid. It’s a toxic protein fragment that dominates the plaques that appear in the brains of people with Alzheimer’s. Many experimental therapies for Alzheimer’s target beta-amyloid, but so far, they’ve not proven effective.

That could be for several reasons. Maybe those treatments started too late to make a difference. But an increasing number of Alzheimer’s researchers are starting to reconsider the field’s emphasis on amyloid. Nature News has a feature this week explaining how the spotlight is shifting to the protein ApoE, encoded by the gene whose variation is responsible for the top genetic risk factor for Alzheimer’s.

In line with this trend, Emory’s Alzheimer’s Disease Research Center recently received a five-year, $7.2 million grant to go beyond the usual suspects like beta-amyloid. Emory will lead several universities in a project to comprehensively examine proteins altered in Alzheimer’s. You’ve heard of the Cancer Genome Atlas? Think of this as the Alzheimer’s Proteome Atlas, potentially addressing the same kind of questions about which changes are the drivers and which are the passengers.

Emory’s back-to-basics proteomics approach has already yielded some scientific fruit, uncovering changes in proteins involved in RNA splicing and processing. Also, the Nature feature also has some background on a clinical trial called TOMMORROW, which Emory’s ADRC is participating in.

Posted on by Quinn Eastman in Neuro Leave a comment

Two heavy hitters in this week’s Nature

Two feature articles in Nature this week on work by Emory scientists.

One is from Virginia Hughes (Phenomena/SFARI/MATTER), delving into Kerry Ressler’s and Brian Dias’ surprising discovery in mice that sensitivity to a smell can be inherited, apparently epigenetically. Coincidentally, Ressler will be giving next week’s Dean’s Distinguished Faculty lecture (March 12, 5:30 pm at the School of Medicine).

Another is from Seattle global health writer Tom Paulson, on immunologist Bali Pulendran and using systems biology to unlock new insights into vaccine design.

Posted on by Quinn Eastman in Immunology, Neuro Leave a comment